Skip to main content
SpringerLink
Log in

Secukinumab, ixekizumab: ulcerative colitis, Crohn's disease

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Orrell KA, et al. Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: A post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program. Journal of the American Academy of Dermatology : 16 Jun 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2018.06.024

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Secukinumab, ixekizumab: ulcerative colitis, Crohn's disease. Reactions Weekly 1710, 10 (2018). https://doi.org/10.1007/s40278-018-48684-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-48684-y

Search

Navigation